Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
-
* Corresponding author: Mark D Williams mardwill@lilly.com
Critical Care 2006, 10:424 doi:10.1186/cc5062
Accesses
- Last 30 days: 12 accesses
- Last year: 161 accesses
- All time: 2867 accesses
Cited by
BioMed Central: 1 citation
|
Letter
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade Critical Care 2006, 10:427 (20 December 2006) |
